Frequency of Bone Marrow Toxicity by Using Pattern of Azathioprine in Inflammatory Bowel Disease Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hyun, Kyung Hee | - |
dc.contributor.author | Lee, Suck-Ho | - |
dc.contributor.author | Shin, Jae Min | - |
dc.contributor.author | Park, Dong Il | - |
dc.contributor.author | Lee, Chang Kyun | - |
dc.contributor.author | Shin, Jeong Eun | - |
dc.contributor.author | Eun, Chang Soo | - |
dc.contributor.author | Huh, Kyu Chan | - |
dc.contributor.author | Hwangbo, Young | - |
dc.date.accessioned | 2021-08-12T02:48:23Z | - |
dc.date.available | 2021-08-12T02:48:23Z | - |
dc.date.issued | 2012-07 | - |
dc.identifier.issn | 1598-9100 | - |
dc.identifier.issn | 2288-1956 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/15039 | - |
dc.description.abstract | Background/Aims: The most important adverse effect of azathioprine (AZA) is bone marrow toxicity (BMT). Many physicians have preferred a gradual dose increment (GDI) policy for the prevention of BMT. The aim of this study was to evaluate the efficacy of GDI for the prevention of AZA-induced BMT in inflammatory bowel disease (IBD) patients. Methods: The medical records of IBD patients who received AZA in 6 university hospitals were reviewed. The patients were divided into two groups: the GDI group (initial dose < 1.5 mg/kg, gradually increased to a therapeutic dose) and the non-GDI group (initial therapeutic dose >= 2 mg/kg). Results: A total of 308 patients were enrolled (male to female ratio, 1: 2.3; mean age, 34.91 +/- 14.19 years; ulcerative colitis, 43.5%; Crohn's disease, 55.2%; and intermediate colitis, 1.3%). The overall incidence of BMT was 16.2% (50/308). BMT developed most frequently between fourth to eighth week (26%, 13/50). The rate of BMT of the non-GDI group was significantly higher than that of the GDI group (27.5%, 11/40 vs. 14.6%, 39/268, P=0.038). A multivariate analysis showed that the only factor related to BMT was a non-GDI policy (P=0.036; odds ratio, 2.41; 95% confidence interval, 1.06-5.49). Conclusions: A GDI policy could be useful for reducing AZA-induced BMT in Korean IBD patients. | - |
dc.format.extent | 7 | - |
dc.language | 한국어 | - |
dc.language.iso | KOR | - |
dc.publisher | 대한장연구학회 | - |
dc.title | Frequency of Bone Marrow Toxicity by Using Pattern of Azathioprine in Inflammatory Bowel Disease Patients | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.5217/ir.2012.10.3.244 | - |
dc.identifier.wosid | 000420058200004 | - |
dc.identifier.bibliographicCitation | Intestinal research, v.10, no.3, pp 244 - 250 | - |
dc.citation.title | Intestinal research | - |
dc.citation.volume | 10 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 244 | - |
dc.citation.endPage | 250 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001684663 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | THIOPURINE METHYLTRANSFERASE ACTIVITY | - |
dc.subject.keywordPlus | TPMT ACTIVITY | - |
dc.subject.keywordPlus | 6-MERCAPTOPURINE | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | PHARMACOGENETICS | - |
dc.subject.keywordPlus | MERCAPTOPURINE | - |
dc.subject.keywordPlus | 6-THIOGUANINE | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | COHORT | - |
dc.subject.keywordAuthor | Inflammatory Bowel Diseases | - |
dc.subject.keywordAuthor | Azathioprine | - |
dc.subject.keywordAuthor | Bone Marrow Toxicity | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.